AR004410A1 - Microgranulos de liberacion prolongada que contienen diltiazem como principio activo - Google Patents

Microgranulos de liberacion prolongada que contienen diltiazem como principio activo

Info

Publication number
AR004410A1
AR004410A1 ARP960105884A ARP960105884A AR004410A1 AR 004410 A1 AR004410 A1 AR 004410A1 AR P960105884 A ARP960105884 A AR P960105884A AR P960105884 A ARP960105884 A AR P960105884A AR 004410 A1 AR004410 A1 AR 004410A1
Authority
AR
Argentina
Prior art keywords
prolonged release
active substance
microgranules containing
release microgranules
containing diltiazem
Prior art date
Application number
ARP960105884A
Other languages
English (en)
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9485856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR004410(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of AR004410A1 publication Critical patent/AR004410A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a nuevas formas de microgránulos de liberación prolongada (LP) que contienen diltiazen. Los microgránulos están constituidospor un soporte granulado neutro revestido con una capa activa que comprende diltiazen o una sal farmacéuticamente aceptable de este último como principioactivo, un agente tensioactivo y un agente aglutinante y una capa externa que asegura la liberación prolongada del principio activo (capa LP).
ARP960105884A 1995-12-22 1996-12-23 Microgranulos de liberacion prolongada que contienen diltiazem como principio activo AR004410A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9515361A FR2742660B1 (fr) 1995-12-22 1995-12-22 Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif

Publications (1)

Publication Number Publication Date
AR004410A1 true AR004410A1 (es) 1998-11-04

Family

ID=9485856

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105884A AR004410A1 (es) 1995-12-22 1996-12-23 Microgranulos de liberacion prolongada que contienen diltiazem como principio activo

Country Status (27)

Country Link
US (3) US6228395B1 (es)
EP (1) EP0868184B1 (es)
JP (1) JP2000506500A (es)
KR (1) KR100354054B1 (es)
CN (1) CN1145488C (es)
AR (1) AR004410A1 (es)
AT (1) ATE238798T1 (es)
AU (1) AU721949B2 (es)
BG (1) BG63770B1 (es)
BR (1) BR9612225A (es)
CA (1) CA2242224C (es)
DE (1) DE69627880T2 (es)
DK (1) DK0868184T3 (es)
EA (1) EA001721B1 (es)
EE (1) EE04045B1 (es)
ES (1) ES2198505T3 (es)
FR (1) FR2742660B1 (es)
GE (1) GEP20022629B (es)
HK (1) HK1018400A1 (es)
HU (1) HU224214B1 (es)
IL (1) IL125047A (es)
NO (1) NO324680B1 (es)
NZ (1) NZ324739A (es)
PL (1) PL186621B1 (es)
PT (1) PT868184E (es)
WO (1) WO1997023219A1 (es)
ZA (1) ZA9610776B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742660B1 (fr) * 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif
US6162463A (en) * 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
FR2831546B1 (fr) * 2001-10-31 2007-03-23 Atofina Materiau polymere thermoplastique pour supports d'enregistrement d'informations audio et/ou optiques
CN1874764B (zh) * 2003-10-10 2012-08-01 埃法尔姆公司 含有银杏提取物的持续释放微粒及其制备方法
US20070122471A1 (en) * 2003-12-25 2007-05-31 Takeda Pharmaceutical Company Limited Method of improving suitability for granulation
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
WO2007149438A2 (en) * 2006-06-19 2007-12-27 Alpharma, Inc. Pharmaceutical compositions
ITFI20110172A1 (it) 2011-08-08 2013-02-09 Valpharma Sa Formulazione multiparticolata a rilascio modificato di diltiazem hcl.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
DK173505B1 (da) * 1987-02-20 2001-01-15 Pharmatec Internat S R L Fremgangsmåde til fremstilling af en diltiazempellet med langsom afgivelse og anvendelse af således fremstillede pelleter t
JPH07552B2 (ja) * 1987-11-06 1995-01-11 田辺製薬株式会社 持効性製剤
FR2623714B1 (fr) * 1987-11-26 1990-04-20 Ethypharm Sa Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
FR2630647B1 (fr) * 1988-04-27 1991-08-16 Sanofi Sa Microbilles de diltiazem, leur procede de fabrication et compositions pharmaceutiques a liberation prolongee les contenant
US5288505A (en) 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5376384A (en) 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
FR2742660B1 (fr) * 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif

Also Published As

Publication number Publication date
CN1207681A (zh) 1999-02-10
US6228395B1 (en) 2001-05-08
WO1997023219A1 (fr) 1997-07-03
ATE238798T1 (de) 2003-05-15
US20020182253A1 (en) 2002-12-05
EA199800593A1 (ru) 1998-12-24
CA2242224C (fr) 2004-01-13
ES2198505T3 (es) 2004-02-01
EE9800197A (et) 1998-12-15
NZ324739A (en) 2000-01-28
FR2742660A1 (fr) 1997-06-27
EE04045B1 (et) 2003-06-16
NO982738L (no) 1998-08-21
US6660296B2 (en) 2003-12-09
KR100354054B1 (ko) 2003-02-14
HU224214B1 (hu) 2005-06-28
DK0868184T3 (da) 2003-08-25
HUP9904129A3 (en) 2000-11-28
EP0868184A1 (fr) 1998-10-07
HUP9904129A2 (hu) 2000-04-28
AU1198397A (en) 1997-07-17
FR2742660B1 (fr) 1998-04-03
KR19990076717A (ko) 1999-10-15
BG102555A (en) 1999-02-26
ZA9610776B (en) 1997-06-30
CA2242224A1 (fr) 1997-07-03
AU721949B2 (en) 2000-07-20
NO982738D0 (no) 1998-06-12
PT868184E (pt) 2003-09-30
IL125047A0 (en) 1999-01-26
DE69627880T2 (de) 2004-03-11
NO324680B1 (no) 2007-12-03
GEP20022629B (en) 2002-02-25
CN1145488C (zh) 2004-04-14
EP0868184B1 (fr) 2003-05-02
HK1018400A1 (en) 1999-12-24
US6383516B1 (en) 2002-05-07
BG63770B1 (bg) 2002-12-29
EA001721B1 (ru) 2001-08-27
PL186621B1 (pl) 2004-02-27
IL125047A (en) 2003-05-29
BR9612225A (pt) 1999-07-13
DE69627880D1 (de) 2003-06-05
JP2000506500A (ja) 2000-05-30
PL327567A1 (en) 1998-12-21

Similar Documents

Publication Publication Date Title
AR004410A1 (es) Microgranulos de liberacion prolongada que contienen diltiazem como principio activo
CO5241353A1 (es) Articulo absorbente en capas
ES2182397T3 (es) Comprimido para la liberacion instantanea y prolongada de una o mas substancias activas.
ES2123323T3 (es) Asociacion de un compuesto con actividad antimicrobiana (por ejemplo lipoaminoacido n,n-octanoilglicina) y de un monoalquileter de glicerol y su uso como agente antimicrobiano.
PT1439829E (pt) Medicamento contendo 3-(3-dimetilamino-1-etil-2-metilpropil)-fenol proporcionando libertacao retardada da substancia activa
ES2119354T3 (es) Microcapsulas que contienen suspensiones de compuestos biologicamente activos.
AR017026A1 (es) Dispositivo de liberacion ininterrumpida de drogas
NO20003159L (no) Dobbelkapsel til administrering av aktive prinsipp ved multippel terapier
ES2167891T3 (es) Estabilizacion de bencimidazoles sensibles a los acidos con combinaciones amino/ciclodextrina.
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
DK1150738T3 (da) Implantat
EE05620B1 (et) Omeprasooli mikrograanulid, nende valmistamismeetod ja farmatseutilised preparaadid
NO961233D0 (no) Orale formuleringer av et antifungalt middel
MX9207263A (es) Sistema para el suministro de una substancia activa para la liberacion sostenida.
ID22878A (id) Komposisi aktif secara terapi
FI941452A (fi) Yhdisteitä, jotka lisäävät muiden sytotoksisten aineiden kasvaimenvastaista aktiivisuutta
FI885603A0 (fi) Milt rengoerings- och vaordmedel foer aostadkommande av en mjuk, glatt hy.
EE200000595A (et) Toimeaine viimine kandjamaatriksisse
DE69826684D1 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen
BR0010571A (pt) Tablete de detergente de composição particulada comprimida
CO5011082A1 (es) Formulacion medicamentosa con liberacion controlada de sus- tancia activa
AR023511A1 (es) Composicion que comprende (s) y (r) 5-amino-3-ciano-1-(2,6-dicloro-4-trifluorometilfenil)-4-trifluoro-metilsulfinilpirazol, dichos compuestos aislados y usos de los mismos como plaguicida
MX24039A (es) Composiciones farmaceuticas que contienen una calcitonina como principio activo.
AR017664A1 (es) Formulaciones farmaceuticas de liberacion sostenida que contienen inhibidores de la alfa-glucosidasa y su uso para la manufactura de un medicamento
ES2033181B1 (es) Una tableta o capsula de herbicida para su aplicacion en arrozales.